Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)
Status: Recruiting
Location: See location...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);
• Patient or healthcare proxy provide informed consent.
Locations
Other Locations
Canada
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITING
Montreal
Contact Information
Primary
Lina Petrella
lina.petrella@affiliate.mcgill.ca
514-934-1934
Time Frame
Start Date: 2025-11-10
Estimated Completion Date: 2030-07
Participants
Target number of participants: 330
Treatments
Experimental: No rifampin
These patients will not receive adjunctive rifampin.
Active_comparator: Adjunctive rifampin
These patients will receive adjunctive rifampin as recommended in guidelines.
Related Therapeutic Areas
Sponsors
Collaborators: Canadian Institutes of Health Research (CIHR), McGill University Health Centre/Research Institute of the McGill University Health Centre, The Peter Doherty Institute for Infection and Immunity, University of Melbourne
Leads: Todd C. Lee MD MPH FIDSA